AR111254A1 - ANHYDING CRYSTALLINE FORMS OF (S) -2- (DIFENYLACEUTIC) -1,2,3,4-TETRAHIDRO-6-METOXI-5- (PHENYLMETOXI) -3-ISOQUINOLINE SODIUM CARBOXYLATE - Google Patents
ANHYDING CRYSTALLINE FORMS OF (S) -2- (DIFENYLACEUTIC) -1,2,3,4-TETRAHIDRO-6-METOXI-5- (PHENYLMETOXI) -3-ISOQUINOLINE SODIUM CARBOXYLATEInfo
- Publication number
- AR111254A1 AR111254A1 ARP180100701A ARP180100701A AR111254A1 AR 111254 A1 AR111254 A1 AR 111254A1 AR P180100701 A ARP180100701 A AR P180100701A AR P180100701 A ARP180100701 A AR P180100701A AR 111254 A1 AR111254 A1 AR 111254A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline forms
- phenylmetoxi
- difenylaceutic
- anhyding
- tetrahidro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Sal sódica de ácido (S)-2-(difenilacetil)-1,2,3,4-tetrahidro-6-metoxi-5-(fenilmetoxi)-3-isoquinolinacarboxílico (EMA401) en formas cristalinas anhidras. Además se divulga el uso de la sal sódica de EMA401 en formas cristalinas anhidras para el tratamiento, la prevención o atenuación de una afección neuropática. Reivindicación 1: Una sal sódica cristalina anhidra de ácido (S)-2-(difenilacetil)-1,2,3,4-tetrahidro-6-metoxi-5-(fenilmetoxi)-3-isoquinolinacarboxílico que exhibe un patrón de difracción de rayos X de polvo que comprende cuatro o más picos, en términos de valores 2q (CuKa l = 1,5418 Å), seleccionados de los picos a 5,6º ± 0,1º, a 6,8º ± 0,1º, a 10,5º ± 0,1º, a 11,3º ± 0,1º, a 13,6º ± 0,1º, a 15,4º ± 0,1º, a 16,4º ± 0,1º, a 18,8º ± 0,1º, a 20,1º ± 0,1º, a 20,9º ± 0,1º, a 22,7º ± 0,1º, a 24,0º ± 0,1º, a 25,4º ± 0,1º, a 27,2º ± 0,1º, a 29,0º ± 0,1º, a 31,2º ± 0,1º, cuando se mide a una temperatura de alrededor de 20 a 25ºC.Sodium salt of (S) -2- (diphenylacetyl) -1,2,3,4-tetrahydro-6-methoxy-5- (phenylmethoxy) -3-isoquinolinecarboxylic acid (EMA401) in anhydrous crystalline forms. In addition, the use of EMA401 sodium salt in anhydrous crystalline forms for the treatment, prevention or attenuation of a neuropathic condition is disclosed. Claim 1: An anhydrous crystalline sodium salt of (S) -2- (diphenylacetyl) -1,2,3,4-tetrahydro-6-methoxy-5- (phenylmethoxy) -3-isoquinolinecarboxylic acid exhibiting a diffraction pattern of X-rays of dust comprising four or more peaks, in terms of 2q values (CuKa l = 1.5418 Å), selected from the peaks at 5.6º ± 0.1º, at 6.8º ± 0.1º, at 10 , 5º ± 0.1º, at 11.3º ± 0.1º, at 13.6º ± 0.1º, at 15.4º ± 0.1º, at 16.4º ± 0.1º, at 18.8º ± 0, 1st, at 20.1º ± 0.1º, at 20.9º ± 0.1º, at 22.7º ± 0.1º, at 24.0º ± 0.1º, at 25.4º ± 0.1º, at 27, 2º ± 0.1º, at 29.0º ± 0.1º, at 31.2º ± 0.1º, when measured at a temperature of around 20 to 25ºC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017077841 | 2017-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111254A1 true AR111254A1 (en) | 2019-06-19 |
Family
ID=61868558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100701A AR111254A1 (en) | 2017-03-23 | 2018-03-23 | ANHYDING CRYSTALLINE FORMS OF (S) -2- (DIFENYLACEUTIC) -1,2,3,4-TETRAHIDRO-6-METOXI-5- (PHENYLMETOXI) -3-ISOQUINOLINE SODIUM CARBOXYLATE |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2019514862A (en) |
| AR (1) | AR111254A1 (en) |
| TW (1) | TW201840539A (en) |
| WO (1) | WO2018172950A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| EP2650011A1 (en) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
| US8551950B2 (en) | 2006-03-20 | 2013-10-08 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis of inflammatory pain |
| KR101125932B1 (en) * | 2006-12-06 | 2012-03-22 | 아이디유엔 파마슈티칼즈, 인코포레이티드 | Crystalline forms of 3s-3-[n-n'-2-tert-butylphenyloxamylalaninyl]amino-5-2',3',5',6'-tetrafluorophenoxy-4-oxopentanoic acid |
| NZ708529A (en) * | 2010-07-21 | 2016-11-25 | Novartis Ag | Salt and solvates of a tetrahydroisoquinoline derivative |
-
2018
- 2018-03-21 JP JP2018553188A patent/JP2019514862A/en active Pending
- 2018-03-21 WO PCT/IB2018/051890 patent/WO2018172950A1/en active Application Filing
- 2018-03-23 AR ARP180100701A patent/AR111254A1/en unknown
- 2018-03-23 TW TW107109961A patent/TW201840539A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201840539A (en) | 2018-11-16 |
| WO2018172950A1 (en) | 2018-09-27 |
| JP2019514862A (en) | 2019-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX371167B (en) | TGF-ß INHIBITORS. | |
| BRPI0621386B8 (en) | pharmaceutical composition for external use | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| ME01992B (en) | Diarylhydantoin compounds | |
| CL2012000033A1 (en) | Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease. | |
| AR082825A2 (en) | HITEROCICLIC INHIBITORS NITROGENATED FROM MEK, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHODS TO PREPARE THEM AND USE OF THE SAME FOR THE TREATMENT OF HYPERPROLIFERATIVE OR INFLAMMATORY DISORDERS | |
| RS52823B (en) | Novel compounds useful for the treatment of degenerative and inflammatory diseases. | |
| EA201290397A1 (en) | 1,3,4-OXADIAZOL-2-CARBOXAMIDE COMPOUND | |
| PE20121337A1 (en) | CRYSTALLINE AND AMORPHOUS FORM OF GENZ 112638 HEMITARTREATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE | |
| RS54485B1 (en) | C7-fluoro substituted tetracycline compounds | |
| ECSP055745A (en) | DERIVATIVES OF 1- (4-BENCIL-PIPERAZIN-1-IL) -3-FENIL-PROPENONA | |
| RS50720B (en) | 3,11-cis-dihydrotetrabenzine for the treatment of a proliferative disease or an inflammation | |
| MX2022016515A (en) | Novel acid secretion inhibitor and use thereof. | |
| AR062394A1 (en) | USE OF COMPOUNDS AND DERIVATIVES OF 2,5-DIHYDROXIBENCEN FOR THE TREATMENT OF PSORIASIS | |
| JOP20190239A1 (en) | Vmat2 inhibitor compounds and compositions thereof | |
| CL2018001407A1 (en) | 1,3,4-thiadiazole compounds and their use in the treatment of cancer | |
| BR112015024075A2 (en) | pyridinylpyrazoloquinoline compounds | |
| CR20200522A (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
| TW200730498A (en) | Compounds | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| AR111254A1 (en) | ANHYDING CRYSTALLINE FORMS OF (S) -2- (DIFENYLACEUTIC) -1,2,3,4-TETRAHIDRO-6-METOXI-5- (PHENYLMETOXI) -3-ISOQUINOLINE SODIUM CARBOXYLATE | |
| CO2018006929A2 (en) | "1,3,4-thiadiazole compounds and their use in the treatment of cancer" | |
| WO2014128228A3 (en) | Medicament | |
| AR077429A1 (en) | HYDROXIASENAPINA COMPOUNDS ITS DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE SAME | |
| RU2009138470A (en) | COMPOSITION FOR EXTERNAL USE ON SKIN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |